Marcus Capone, Amber Capone
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psychedelic-assisted therapy field emphasizes establishing trust, safety, and reputability through professional guidelines, standards, and certification systems. Session discusses current developments in certification requirements and supportive infrastructure.
Brigadier General (Ret) Stephe…, Natalie Gukasyan, Shannon Carlin, Will Van Derveer
Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case
Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper
Panel discusses equipping parents with youth drug use info, fostering open conversations, and addressing public perception. Transformative drug education empowers communities, dismantles stigma, and cultivates informed society.
Vilmarie Narloch, Rhana Hashemi, Stefanie Jones, Gina Giorgio
Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.
Paul Summergrad, Tom Insel, Rachel Nuwer
Vicky Dulai of Compassion For Addiction moderates a discussion with Amy Emerson of MAPS Public Benefit Corporation and Rachel Yehuda of Icahn School of Medicine on leadership in the psychedelic
Rachel Yehuda
Michael Pollan, an influential author, sparked interest in psychedelic research with his book "How to Change Your Mind." Bob Jesse, a key figure in the resurgence of psychedelics, has made
Robert Jesse, Michael Pollan
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon
MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.
Keren Tzarfaty, Michael Mithoefer, Julie Holland
TREAT California initiative aims to transform mental healthcare in California with $5 Billion funding for psychedelic medicine research and access, inspired by successful stem cell agency model.
Jeannie Moller Fontana